83 related articles for article (PubMed ID: 9023843)
21. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.
Gasinska A; Fowler JF; Lind BK; Urbanski K
Acta Oncol; 2004; 43(7):657-66. PubMed ID: 15545186
[TBL] [Abstract][Full Text] [Related]
22. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial.
Dobrowsky W; Huigol NG; Jayatilake RS; Kizilbash NI; Okkan S; Kagiya VT; Tatsuzaki H
Radiother Oncol; 2007 Jan; 82(1):24-9. PubMed ID: 17161478
[TBL] [Abstract][Full Text] [Related]
23. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
Kim YB; Cho JH; Keum KC; Lee CG; Seong J; Suh CO; Kim GE
Gynecol Oncol; 2007 Jan; 104(1):58-63. PubMed ID: 16919718
[TBL] [Abstract][Full Text] [Related]
24. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
25. rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K; Gascón P; Sigounas G; Jolliffe L
Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
[TBL] [Abstract][Full Text] [Related]
26. Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy.
Sood BM; Gorla GR; Garg M; Anderson PS; Fields AL; Runowicz CD; Goldberg GL; Vikram B
Cancer; 2003 Apr; 97(7):1781-8. PubMed ID: 12655536
[TBL] [Abstract][Full Text] [Related]
27. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
[TBL] [Abstract][Full Text] [Related]
28. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence.
Viswanathan AN; Deavers MT; Jhingran A; Ramirez PT; Levenback C; Eifel PJ
Gynecol Oncol; 2004 Apr; 93(1):27-33. PubMed ID: 15047210
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
30. Radiation therapy to a primary tumor accelerates metastatic growth in mice.
Camphausen K; Moses MA; Beecken WD; Khan MK; Folkman J; O'Reilly MS
Cancer Res; 2001 Mar; 61(5):2207-11. PubMed ID: 11280788
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment.
Moeller BJ; Richardson RA; Dewhirst MW
Cancer Metastasis Rev; 2007 Jun; 26(2):241-8. PubMed ID: 17440683
[TBL] [Abstract][Full Text] [Related]
32. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia.
Nakano T; Suzuki Y; Ohno T; Kato S; Suzuki M; Morita S; Sato S; Oka K; Tsujii H
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2185-90. PubMed ID: 16609033
[TBL] [Abstract][Full Text] [Related]
33. Apoptotic index as predictive marker for radiosensitivity of cervical carcinoma: evaluation of membrane fluidity, biochemical parameters and apoptosis after the first dose of fractionated radiotherapy to patients.
Bhosle SM; Huilgol NG; Mishra KP
Cancer Detect Prev; 2005; 29(4):369-75. PubMed ID: 16125335
[TBL] [Abstract][Full Text] [Related]
34. Translational research offers individually tailored treatments for cancer patients.
Bartelink H; Begg AC; Martin JC; van Dijk M; Moonen L; van 't Veer LJ; Van de Vaart P; Verheij M
Cancer J Sci Am; 2000; 6(1):2-10. PubMed ID: 10696731
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment proliferation parameters do not add predictive power to clinical factors in cervical cancer treated with definitive radiation therapy.
Tsang RW; Juvet S; Pintilie M; Hill RP; Wong CS; Milosevic M; Chapman W; Levin W; Manchul LA; Fykes AW
Clin Cancer Res; 2003 Oct; 9(12):4387-95. PubMed ID: 14555510
[TBL] [Abstract][Full Text] [Related]
36. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
[TBL] [Abstract][Full Text] [Related]
37. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
38. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
39. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions.
De Los Santos JF; Small W
Semin Oncol; 2004 Dec; 31(6 Suppl 18):37-41. PubMed ID: 15726521
[TBL] [Abstract][Full Text] [Related]
40. Modulating the radiation response.
Coleman CN
Stem Cells; 1996 Jan; 14(1):10-5. PubMed ID: 8820945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
